Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yara Dadalti Fragoso, Tarso Adoni, Andrea Anacleto, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Rinaldo Claudino, Alfredo Damasceno, Maria Lucia Brito Ferreira, Paulo Diniz da Gama, Marcus Vinicus Magno Goncalves, Anderson Kuntz Grzesiuk, Andre Palma da Cunha Matta & Monica Fiuza Koncke Parolin. (2014) How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?. Expert Review of Neurotherapeutics 14:11, pages 1251-1260.
Read now
Read now
Masaaki Niino. (2011) Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab. Degenerative Neurological and Neuromuscular Disease 1, pages 33-42.
Read now
Read now
Articles from other publishers (26)
Alessandra Sottini, Virginia Quaresima, Mosè Barbaro, Lucia Moiola, Massimo Filippi, Maria Malentacchi, Marco Capobianco, Marco Puthenparampil, Paolo Gallo, Eleonora Cocco, Jessica Frau, Mauro Zaffaroni, Clara Guaschino, Chiara Stampatori, Chiara Mancinelli, Laura Brambilla, Valentina Torri Clerici, Marika Vianello, Francesca Vitetta, Diana Ferraro, Pamela Rosettani, Maura Chiara Danni, Marta Conti, Maria Grimoldi, Ruggero Capra & Luisa Imberti. (2023) Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab. Journal of Neuroimmunology 382, pages 578170.
Crossref
Crossref
Gurjit Kaur Bhatti, Harsh Vikram Singh, Eva Sharma, Abhishek Sehrawat, Jayapriya Mishra, Umashanker Navik, P. Hemachandra Reddy & Jasvinder Singh Bhatti. 2023. Treatments, Nutraceuticals, Supplements, and Herbal Medicine in Neurological Disorders. Treatments, Nutraceuticals, Supplements, and Herbal Medicine in Neurological Disorders
453
482
.
Mrugank Pandya, Bappaditya Chatterjee & Srikar Ganti. (2022) Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints
and Recent Development. Current Pharmaceutical Design 28:31, pages 2538-2553.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
643
766
.
Mark S. Freedman, Daniel Selchen, Alexandre Prat & Paul S. Giacomini. (2018) Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45:5, pages 489-503.
Crossref
Crossref
Marta Tejera-Alhambra, Lidia Fernández-Paredes, Clara de Andrés & Silvia Sánchez-Ramón. (2016) Multiple Sclerosis: Where Do We Go From Here?. EMJ Neurology, pages 84-95.
Crossref
Crossref
Katja ThomasJudith EiseleFrancisco Alejandro Rodriguez-LealUndine HainkeTjalf Ziemssen. (2016) Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurology Neuroimmunology & Neuroinflammation 3:3.
Crossref
Crossref
Duncan J. Topliss. (2016) Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases. Endocrinology and Metabolism 31:4, pages 493.
Crossref
Crossref
Emily V. Stevenson, Jeanie McGee, Jonathan S. Alexander & Alireza Minagar. 2016. Multiple Sclerosis. Multiple Sclerosis
13
21
.
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
23
66
.
Erwin De Genst, Dimitri Y. Chirgadze, Fabrice A.C. Klein, David C. Butler, Dijana Matak-Vinković, Yvon Trottier, James S. Huston, Anne Messer & Christopher M. Dobson. (2015) Structure of a Single-Chain Fv Bound to the 17 N-Terminal Residues of Huntingtin Provides Insights into Pathogenic Amyloid Formation and Suppression. Journal of Molecular Biology 427:12, pages 2166-2178.
Crossref
Crossref
Shirin Attarian, Cindy Y. Wang, Jorge Romero, Stefan K. Barta, Santiago Aparo & Mark A. Menegus. (2014) Alemtuzumab induced ST-segment elevation and acute myocardial dysfunction. Journal of Cardiology Cases 10:5, pages 176-179.
Crossref
Crossref
Alireza Minagar. (2014) Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 6:4, pages 1-117.
Crossref
Crossref
P S Rommer, U K Zettl, B Kieseier, H-P Hartung, T Menge, E Frohman, B M Greenberg, B Hemmer & O Stüve. (2014) Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology 175:3, pages 397-407.
Crossref
Crossref
P S Rommer, A Dudesek, O Stüve & UK Zettl. (2014) Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology 175:3, pages 373-384.
Crossref
Crossref
Rehiana Ali, Richard St John Nicholas & Paolo Antonio Muraro. (2013) Drugs in Development for Relapsing Multiple Sclerosis. Drugs 73:7, pages 625-650.
Crossref
Crossref
Teya M. Tietje, Douglas R. Allington & Michael P. Rivey. (2013) Alemtuzumab: A Place in Therapy for Treatment of Multiple Sclerosis. International Journal of Clinical Medicine 04:10, pages 459-471.
Crossref
Crossref
Mark D. CossburnKatharine HardingGillian IngramTariq El-ShanawanyAdrian HeapsTrevor P. PickersgillStephen JollesNeil P. Robertson. (2013) Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 80:1, pages 55-61.
Crossref
Crossref
Alireza Minagar. (2013) Current and Future Therapies for Multiple Sclerosis. Scientifica 2013, pages 1-11.
Crossref
Crossref
Kenneth C. Gorson. (2012) An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic Advances in Neurological Disorders 5:6, pages 359-373.
Crossref
Crossref
Amedeo Amedei, Domenico Prisco & Mario D’Elios. (2012) Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies. International Journal of Molecular Sciences 13:12, pages 13438-13460.
Crossref
Crossref
Soile TuomelaVerna SaloSubhash K. TripathiZhi ChenKirsti LaurilaBhawna GuptaTarmo Äijö, Lotta OikariBrigitta Stockinger, Harri Lähdesmäki & Riitta Lahesmaa. (2012) Identification of early gene expression changes during human Th17 cell differentiation. Blood 119:23, pages e151-e160.
Crossref
Crossref
Shyi-Jou Chen, Yen-Ling Wang, Hueng-Chuen Fan, Wen-Tsung Lo, Chih-Chien Wang & Huey-Kang Sytwu. (2012) Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis. Clinical and Developmental Immunology 2012, pages 1-16.
Crossref
Crossref
Michael G. Tovey & Christophe Lallemand. (2011) Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety 2:3, pages 113-128.
Crossref
Crossref
S. Oddo, A. Laroni, A. Uccelli & M. Giusti. (2014) A case of thyroiditis during natalizumab therapy for multiple sclerosis. Journal of Endocrinological Investigation 34:5, pages 408-409.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2011. The Handbook of Neuroprotection. The Handbook of Neuroprotection
409
483
.